Tobacco Law Means Drug Sponsor Opportunities May Not Stop At Cessation
This article was originally published in The Tan Sheet
Executive Summary
The tobacco control act prompts FDA to consider new indications - such as smoking reduction - for smoking cessation products, which could lead to new criteria for application approval
You may also be interested in...
FDA Delves Into Broader Smoking Cessation Approach
FDA’s questions for comments in a notice for a public hearing on smoking cessation approaches suggest a willingness to take an expanded approach to nicotine replacement therapy approvals and indications. Discussion topics include fast-track and accelerated approval authorities for NRTs and extended use of the products.
FDA Delves Into Broader Smoking Cessation Approach
FDA’s questions for comments in a notice for a public hearing on smoking cessation approaches suggest a willingness to take an expanded approach to nicotine replacement therapy approvals and indications. Discussion topics include fast-track and accelerated approval authorities for NRTs and extended use of the products.
FDA Will Mull OTC Smoking Cessation Long-Term Use As Support Builds
Participants at an FDA workshop will consider issues that could influence whether the agency extends the use of nicotine-replacement therapies beyond the current 12-week indication